Want to see TGTX full AI Analyst Report?
TG Therapeutics (TGTX) Ratios
TG Therapeutics Ratios
TGTX's free cash flow for Q2 2026 was $38.97M. For the 2026 fiscal year, TGTX's free cash flow was decreased by $-293.00K and operating cash flow was $39.26M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.10 | 6.25 | 5.92 | 3.16 | 5.06 |
| Quick Ratio | 3.29 | 5.03 | 5.18 | 3.16 | 5.06 |
| Cash Ratio | 0.51 | 1.98 | 1.73 | 1.92 | 4.57 |
| Solvency Ratio | 1.08 | 0.07 | 0.08 | -1.65 | -2.44 |
| Operating Cash Flow Ratio | -0.16 | -0.45 | -0.58 | -3.31 | -4.52 |
| Short-Term Operating Cash Flow Coverage | -23.73 | 0.00 | 0.00 | 0.00 | -303.21 |
| Net Current Asset Value | $ 215.53M | $ 211.03M | $ 148.86M | $ 33.29M | $ 188.49M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.25 | 0.44 | 0.34 | 0.43 | 0.21 |
| Debt-to-Equity Ratio | 0.40 | 1.14 | 0.69 | 1.42 | 0.33 |
| Debt-to-Capital Ratio | 0.29 | 0.53 | 0.41 | 0.59 | 0.25 |
| Long-Term Debt-to-Capital Ratio | 0.28 | 0.52 | 0.38 | 0.55 | 0.22 |
| Financial Leverage Ratio | 1.64 | 2.60 | 2.05 | 3.30 | 1.60 |
| Debt Service Coverage Ratio | 17.07 | 1.98 | 2.04 | -20.91 | -51.71 |
| Interest Coverage Ratio | 4.61 | 1.75 | 1.64 | -21.42 | -61.15 |
| Debt to Market Cap | 0.06 | 0.06 | 0.04 | 0.04 | 0.03 |
| Interest Debt Per Share | 1.99 | 1.91 | 0.87 | 0.69 | 0.64 |
| Net Debt to EBITDA | 1.35 | 1.48 | 0.68 | 0.09 | 0.64 |
| Profitability Margins | |||||
| Gross Profit Margin | 83.66% | 88.30% | 93.95% | 90.48% | 88.19% |
| EBIT Margin | 21.76% | 15.08% | 10.99% | -7670.41% | -5119.79% |
| EBITDA Margin | 21.80% | 15.17% | 11.17% | -7651.92% | -5112.41% |
| Operating Profit Margin | 20.01% | 12.74% | 8.83% | -7838.99% | -5154.28% |
| Pretax Profit Margin | 17.43% | 7.78% | 5.59% | -8036.34% | -5204.08% |
| Net Profit Margin | 72.56% | 7.11% | 5.42% | -8036.34% | -5204.08% |
| Continuous Operations Profit Margin | 72.56% | 7.11% | 5.42% | -8036.34% | -5204.08% |
| Net Income Per EBT | 416.41% | 91.36% | 97.01% | 100.00% | 100.00% |
| EBT Per EBIT | 87.08% | 61.04% | 63.31% | 102.52% | 100.97% |
| Return on Assets (ROA) | 42.06% | 4.05% | 3.84% | -115.62% | -91.70% |
| Return on Equity (ROE) | 69.01% | 10.52% | 7.90% | -382.02% | -146.78% |
| Return on Capital Employed (ROCE) | 13.56% | 8.61% | 7.48% | -155.53% | -109.71% |
| Return on Invested Capital (ROIC) | 13.54% | 7.85% | 7.22% | -153.80% | -108.88% |
| Return on Tangible Assets | 42.06% | 4.05% | 3.85% | -116.10% | -91.89% |
| Earnings Yield | 10.39% | 0.53% | 0.52% | -13.97% | -13.86% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.02 | 2.55 | 4.57 | 0.00 | 4.82 |
| Payables Turnover | 0.94 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.80 | 0.35 | 0.35 | 0.00 | 0.00 |
| Fixed Asset Turnover | 98.17 | 46.01 | 29.03 | 0.26 | 0.60 |
| Asset Turnover | 0.58 | 0.57 | 0.71 | 0.01 | 0.02 |
| Working Capital Turnover Ratio | 1.29 | 0.89 | 1.23 | 0.01 | 0.02 |
| Cash Conversion Cycle | 246.53 | 1190.90 | 1108.43 | 0.00 | 75.79 |
| Days of Sales Outstanding | 181.01 | 143.32 | 79.81 | 0.00 | 75.79 |
| Days of Inventory Outstanding | 455.14 | 1047.58 | 1028.62 | 0.00 | 0.00 |
| Days of Payables Outstanding | 389.62 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 636.15 | 1190.90 | 1108.43 | 0.00 | 75.79 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.17 | -0.28 | -0.22 | -1.30 | -2.24 |
| Free Cash Flow Per Share | -0.17 | -0.28 | -0.22 | -1.30 | -2.24 |
| Dividend Paid and CapEx Coverage Ratio | -115.76 | -900.38 | 0.00 | -12583.57 | -737.24 |
| Capital Expenditure Coverage Ratio | -115.76 | -900.38 | 0.00 | -12583.57 | -737.24 |
| Operating Cash Flow Coverage Ratio | -0.10 | -0.16 | -0.28 | -2.12 | -3.74 |
| Operating Cash Flow to Sales Ratio | -0.04 | -0.12 | -0.13 | -63.26 | -44.20 |
| Free Cash Flow Yield | -0.58% | -0.93% | -1.30% | -11.00% | -11.78% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 9.62 | 188.13 | 191.33 | -7.16 | -7.22 |
| Price-to-Sales (P/S) Ratio | 6.98 | 13.29 | 10.38 | 575.19 | 375.58 |
| Price-to-Book (P/B) Ratio | 6.64 | 19.67 | 15.11 | 27.34 | 10.59 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -172.18 | -107.84 | -77.18 | -9.09 | -8.49 |
| Price-to-Operating Cash Flow Ratio | -173.67 | -107.96 | -77.18 | -9.09 | -8.50 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | 2.38 | -1.80 | 0.16 | -0.83 |
| Enterprise Value Multiple | 33.37 | 89.13 | 93.58 | -7.43 | -6.70 |
| Enterprise Value | 4.48B | 4.45B | 2.44B | 1.58B | 2.29B |
| EV to EBITDA | 33.37 | 89.13 | 93.58 | -7.43 | -6.70 |
| EV to Sales | 7.28 | 13.52 | 10.45 | 568.28 | 342.71 |
| EV to Free Cash Flow | -179.45 | -109.66 | -77.75 | -8.98 | -7.74 |
| EV to Operating Cash Flow | -181.00 | -109.78 | -77.75 | -8.98 | -7.75 |
| Tangible Book Value Per Share | 4.49 | 1.53 | 1.13 | 0.43 | 1.79 |
| Shareholders’ Equity Per Share | 4.49 | 1.53 | 1.13 | 0.43 | 1.79 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -3.16 | 0.09 | 0.03 | 0.00 | 0.00 |
| Revenue Per Share | 4.27 | 2.26 | 1.65 | 0.02 | 0.05 |
| Net Income Per Share | 3.10 | 0.16 | 0.09 | -1.65 | -2.63 |
| Tax Burden | 4.16 | 0.91 | 0.97 | 1.00 | 1.00 |
| Interest Burden | 0.80 | 0.52 | 0.51 | 1.05 | 1.02 |
| Research & Development to Revenue | 0.26 | 0.29 | 0.33 | 45.01 | 33.28 |
| SG&A to Revenue | 0.38 | 0.47 | 0.53 | 34.29 | 19.15 |
| Stock-Based Compensation to Revenue | 0.10 | 0.13 | 0.16 | 6.89 | 9.16 |
| Income Quality | -0.06 | -1.73 | -2.48 | 0.89 | 0.85 |
Currency in USD
